Drug Trial Radar · NCT07255664
A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC
Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Nov 13, 2025
Primary completion
Apr 2027
Study completion Apr 2029
Sponsor
- Lead sponsor
- CuraCell TX ABIndustry
- Sponsor type
- Industry
- Collaborators
- Zellwerk GmbH; Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Krebsforschung Rhein-Main e.V.
- First posted
- Dec 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a First-In-Human trial investigating a novel expansion protocol of an ATIMP (CC-38), composed of autologous TIL.
Conditions
- Metastatic Colorectal Cancer
- Prostate Cancer Metastatic
- Prostate Cancer Locally Advanced
Interventions
CC-38Drug
CC-38 drug product is an autologous ATIMP composed of in vitro expanded tumor-infiltrating T-lymphocytes.
PembrolizumabDrug
A concomitant IMP is pembrolizumab
CyclophosphamidDrug
Cyclophosphamid is used as a AxMP
Interleukin-2Drug
Interleukin-2 is used as a AxMP.
UromitexanDrug
Uromitexan is used as a AxMP.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of safety, tolerability, and feasibility of repeated administrations of the novel ATIMP, CC-38.Time frame: 42 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Krankenhaus Nordwest
Frankfurt, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.